Gynecologic imaging: Current and emerging applications
VR Iyer, SI Lee
Department of Radiology, Massachusetts General Hospital, White 270, 55 Fruit Street, Boston MA 02114, USA
V R Iyer
Department of Radiology, Massachusetts General Hospital, White 270, 55 Fruit Street, Boston MA 02114
Common diagnostic challenges in gynecology and the role of imaging in their evaluation are reviewed. Etiologies of abnormal uterine bleeding identified on pelvic sonography and sonohysterography are presented. An algorithmic approach for characterizing an incidentally detected adnexal mass and use of magnetic resonance imaging for definitive diagnosis are discussed. Finally, the role of F18-fluorodeoxyglucose positron emission tomography in the management of gynecological malignancies, and pitfalls associated with their use are examined.
|How to cite this article:|
Iyer V R, Lee S I. Gynecologic imaging: Current and emerging applications.J Postgrad Med 2010;56:117-124
|How to cite this URL:|
Iyer V R, Lee S I. Gynecologic imaging: Current and emerging applications. J Postgrad Med [serial online] 2010 [cited 2021 Dec 6 ];56:117-124
Available from: https://www.jpgmonline.com/text.asp?2010/56/2/117/65285
Imaging plays a pivotal role in resolving common complaints that present to a gynecologist's practice. It has a central role in the workup of abnormal uterine bleeding. Imaging also has wide applications in diagnosing incidentally detected adnexal masses. Positron emission tomography/computed tomography (PET/CT) has several emerging applications in the management of gynecological malignancies. These key issues that radiologists must keep abreast of to reach conclusive diagnoses are discussed in this review.
Evaluation of Abnormal Uterine Bleeding with Ultrasound and Sonohysterography
Although abnormal uterine bleeding (AUB) is most commonly caused by hormonal imbalance, it can be a presenting feature of endometrial polyps, hyperplasia or cancer of the cervix or endometrium.  About 20% of postmenopausal bleeding is a manifestation of gynecologic malignancy, most commonly arising from the cervix or endometrium.  Endometrial cancer accounts for approximately 10% of AUB in postmenopausal women (and is likely to be lower in premenopausal women). However, as AUB is the most common presenting sign of endometrial cancer, which is curable in early stages, imaging is directed towards its diagnosis.
Imaging for diagnosis of AUB begins with transvaginal ultrasonography (TVUS), which is widely available, well-tolerated and noninvasive. The appearance of normal and abnormal endometrium in pre- and postmenopausal women is described below.
In a premenopausal woman, the endometrium consists of a superficial functional layer and a deep basal layer. Thickness and echogenicity of normal endometrium change during the menstrual cycle. , In the early proliferative phase (Days 5 to 9), the endometrium is relatively thin and displays an echogenicity similar to that of the myometrium. In the late proliferative phase (Days 10 to 14), the superficial portion of the endometrium is hypoechoic, whereas the deep portion of the endometrium appears as a uniformly echogenic band.  This gives the characteristic multilayered appearance of the periovulatory endometrium. Endometrial thickness and echogenicity steadily increase in the secretory phase (Days 14 to 27). By the end of the secretory phase, the entire endometrium is hyperechoic. Endometrial thickness should be measured on a sagittal image of the uterus.  The thickness of the endometrium in different menstrual phases is presented in [Table 1].  However, this normal variation in endometrial thickness compromises the utility of TVUS in the evaluation of AUB in this population. In general, a thickness of >16 mm in a symptomatic patient is considered abnormal but with sensitivity of 67% and specificity of 75%. 
The normal postmenopausal endometrium should appear thin, homogeneous and echogenic. Double-layer endometrial thickness less than 5 mm without focal thickening is consistent with atrophy.  Endometrial thickness greater than 5 mm (measured on TVUS) is highly sensitive for detecting endometrial cancer in postmenopausal women with AUB. It is more sensitive than other invasive diagnostic methods such as endometrial biopsy or sonohysterography for diagnosing endometrial cancer in this population [Table 2]. ,,,,,
The endometrium in a woman undergoing hormone replacement therapy (HRT) may vary up to 3 mm if cyclic estrogen and progesterone therapy is being used. In asymptomatic patients, a thickness of up to 8 mm is considered normal. If a patient receiving HRT presents with AUB, endometrial thickness ≥5 mm warrants further workup.  However, more recent findings suggest that a thickness of 8 mm, and not 5 mm, on TVUS may be a more appropriate cutoff point for endometrial biopsy in symptomatic patients. 
Tamoxifen is a selective estrogen receptor modulator used in the treatment of breast cancer and has a weak estrogen-agonist effect in the uterus. In asymptomatic postmenopausal women treated with tamoxifen, endometrial thickness greater than 6 mm on TVUS suggests an abnormality.  In symptomatic patients, however, a cutoff of 5 mm warrants further investigation. The thickness of the endometrium increases with duration of tamoxifen therapy. 
If the endometrium appears abnormal in thickness or morphology, the next step in the diagnosis of AUB is nonfocal endometrial biopsy. In premenopausal women with AUB unresponsive to hormonal therapy and risk factors for endometrial cancer (age >35 years, morbid obesity, chronic diabetes or hypertension, or chronic tamoxifen usage), endometrial biopsy is recommended irrespective of TVUS findings.
If TVUS shows normal endometrial thickness, or if biopsy findings are benign, a search must be initiated for focal pathology to explain the AUB. Sonohysterography and hysteroscopy are both highly accurate in detecting focal endometrial pathology, such as subendometrial fibroid and endometrial polyps [Table 2]. Sonohysterography involves placement of a 5F catheter through the cervix and distension of the uterine cavity with sterile normal saline ( 
Submucosal fibroids appear as broad-based, hypoechoic, well-defined solid masses with shadowing. An overlying layer of echogenic endometrium confirms their subendometrial location, thus distinguishing them from endometrial polyps. In contrast to endometrial polyps, submucosal fibroids distort the endometrial-myometrial interface and show acoustic attenuation.  Pedunculated submucosal fibroids, fibroids that have prolapsed into the endocervical canal and fibroids with a multilobulated surface are unusual presentations. 
Sonohysterography is less useful for characterizing diffuse lesions like hyperplasia and endometrial carcinoma. Endometrial hyperplasia appears as a diffuse thickening of the echogenic endometrial stripe without focal abnormality. Distinguishing focal endometrial hyperplasia from polyps is difficult because of similar characteristics of focal endometrial thickening. 
Endometrial cancer should be suspected when the single layer of endometrium is thicker than 8 mm, irregular, broad-based, or the endometrial-myometrial junction is lost. Single layer thickness  Chronic tamoxifen therapy is associated with higher rates of endometrial pathologies, including cancer. In addition, cystic subendometrial atrophy is also seen which results in an apparently increased thickness on TVUS evaluation. In such patients sonohysterography is useful in localizing the pathology to either the endometrium or the inner myometrium. However, cystic hypertrophy is, at times, extensive enough to be mistaken for diffuse or focal endometrial thickening, even at sonohysterography. 
Evaluation of the Incidental Adnexal Mass with US, CT and MRI
Incidental adnexal masses encountered on sonography pose a challenging problem because features of benign and malignant adnexal masses overlap. Majority of malignant ovarian neoplasms have a rapid rate of growth, and complete surgical resection has been shown to improve prognosis. Thus, surgery is usually indicated if imaging features cannot adequately characterize the lesion as benign. In order to prevent unnecessary oophorectomies, while not missing early malignancy, the goal of imaging must be to confidently assess a lesion as benign and refer all indeterminate lesions expeditiously for surgical evaluation [Figure 2].
A wide range of sensitivity and specificity have been reported with US ranging from 84-97%, and 56-95%, respectively for the detection of ovarian malignancies. ,,,,, While readily available and a powerful first step, US performance is limited by operator variability and patient body habitus. Thus, when an adnexal mass is indeterminate on US, MRI has been shown to be more useful than CA-125 or CT as the follow-up test  as it can definitively characterize as benign certain lesions that are indeterminate on ultrasound.
Extra-ovarian adnexal lesions, whether solid or cystic, are likely to be benign and should be followed up with MRI, a useful adjunctive in reaching a definitive diagnosis. Solid-appearing ovarian lesions in both premenopausal and postmenopausal women and cystic ovarian lesions in postmenopausal women should be followed up with MRI, which can accurately characterize them as benign.
Most intra-ovarian cysts in premenopausal women are functional. A premenopausal woman with a cystic ovarian lesion with some features of benign lesions should be followed up with MRI, which can aid in reaching a conclusive diagnosis. Lesions with features suggestive of malignancy, e.g. irregular and thick walls and septa, papillary projections or large amount of ascites, should be referred for surgical evaluation.  However, if the lesion is a complex cyst with no definite features of either malignancy or benignity, it should be followed up with sonography in six weeks, then referred for surgical evaluation if it persists.
Common extra-ovarian lesions include pedunculated and broad-ligament fibroids, hydro- or pyosalpinx, parovarian cyst and peritoneal inclusion cysts, all of which can be well-characterized by MRI. Certain intra-ovarian lesions like dermoids, endometriomas and fibromas also have some classic MRI features.
Pedunculated and Broad-Ligament Fibroid
Although most fibroids can be identified on US, small subserosal pedunculated fibroids and fibroids arising from the broad ligament can be difficult to characterize on TVUS as arising outside the ovary. The US appearance is variable, ranging from hypoechoic or echogenic with or without acoustic shadowing. On MRI, fibroids are well-rounded, discretely-marginated structures with a whirling internal architecture. Signal intensity on T1 and T2 weighted images and enhancement pattern varies widely. Continuity with the uterine myometrium establishes the diagnosis of subserosal myoma. ,, MRI can demonstrate the presence of normal ovaries, separate from the adnexal mass.
Fibromas, Thecomas and Fibrothecomas
These are the most common types of ovarian sex-cord stromal tumors, and together represent 8% of ovarian neoplasms.  On US a hypoechoic and attenuating mass within the ovary is characteristic. In cases where there is no attenuation and when the ovarian origin is doubtful, MRI features are helpful. On MRI, fibromas and fibrothecomas are well-marginated ovarian lesions with homogeneous internal architecture, isointense on T1 images, and hypointense on T2 images with low-level gadolinium enhancement. 
The most common US appearance of endometrioma [Figure 3] is that of a hypoechoechoic lesion within the ovary which has diffuse low-level internal echoes.  The presence of hyperechoic foci in the wall, different from the wall nodularity seen in malignant lesions, increases the confidence in diagnosis; 4.9% of endometriomas appear solid on sonography.  MRI helps in the characterization of endometriomas when US imaging features are inconclusive or if malignant degeneration is suspected. On MRI, endometriomas appear as "light-bulb" bright lesions on T1 weighted images, due to the high concentration of blood products. A T2 "shading" effect has been described due to the varying effect of the blood products [Figure 3]. Punctate or plaque-like T1 bright lesions in the pelvis, irrespective of the T2 signal also indicate endometriosis. Enhancement of the solid portions should raise concern for malignancy. 
Mature cystic teratomas are composed of tissue of ectodermal, mesodermal and endodermal origin, with a predominance of ectodermal tissue. They are bilateral in 10% of cases and more common in women in the reproductive age group. Dermoids are usually unilocular cysts filled with sebaceous material and with a solid mural nodule consisting of teeth, hair or sebaceous material. The sonographic appearance of a dermoid is a cystic lesion with a densely echogenic tubercle [Figure 4]. It can also appear as a diffusely or partially echogenic mass with sound attenuation or as a cystic mass with thin echogenic bands.  MRI identifies macroscopic fat in dermoids as T1 bright lesions  that lose signal on fat saturation sequences. A few dermoids do not contain macroscopic fat, but lipid is present in the cyst wall and in the Rokitansky nodule. In these cases, gradient-recalled opposed-phase imaging can demonstrate loss of signal within the wall or nodule.  The solid portion of dermoids demonstrate restricted diffusion on diffusion-weighted imaging (DWI). 
Tubo-ovarian Abscess, Hydrosalpinx and Pyosalpinx
The natural history of pelvic inflammatory disease is progression from a phase of acute salpingitis to involvement of the ovary in the form of a tubo-ovarian complex. Further breakdown of the adnexal architecture results in a tubo-ovarian abscess (TOA). In the acute phase, the wall of the fallopian tube becomes edematous and thickened. The fimbrial occludes, causing the tube to fill with pus and fold on itself. On US, the folding of the tube gives rise to the appearance of incomplete septa on longitudinal sections. On cross-section, the "cog-wheel" appearance is noted due to the sonolucent tube with inflammed endosalpingeal folds. Chronic disease leads to hydrosalpinx which appears sonolucent with hyperechoic projections on the wall, due to the flattened endosalpingeal folds.  On CT, an adnexal mass with uniformly thick, enhancing walls, regular, thickened septa and a thickened mesosalpinx are indicative of a TOA. Gas bubbles, when seen in the mass, are diagnostic. 
On MRI, pyosalpinx and hydrosalpinx are tortuous, elongated adnexal lesions. Wall thickening and contrast enhancement,  as well as enhancement of the surrounding inflammation are seen in pyosalpinx. The signal intensity of the mass depends on the protein content. However, they are typically hyperintense on T2 weighted images with areas of shading and hypointensity in the periphery. On DWI, TOAs, similar to most abscesses, demonstrate restricted diffusion.
Peritoneal Inclusion Cyst
Inflammation and adhesions of the pelvic peritoneum traps fluid secreted by the normal ovary, giving rise to peritoneal inclusion cysts. The US appearance is that of a multilocular cyst, with thin walls and septation, surrounding the ovary.  Fine peritoneal adhesions extend to and distort the ovary, but do not penetrate the parenchyma. When the ovary is thus entrapped, it appears like a "spider in a web".  The cysts can be mistaken for hemorrhagic cysts, hydrosalpinx, pyosalpinx, serous or mucinous cystadenoma, malignant ovarian lesions or dermoid cyst.  MRI helps in definitive diagnosis of the entity when a normal ovary cannot be identified on sonography, ipsilateral to the multiloculated cyst. The T1 hypo- and T2 hyperintense cysts have a thin pseudo-wall formed by pelvic organs, bowel and the pelvic wall, and conform to the shape of the surrounding space.
Physiological Cysts and Hemorrhagic Cysts
Follicular or corpus luteal cysts can be seen on US depending on the menstrual phase. On US, follicular cysts are smaller than 5 cm in size, thin-walled, sharp-margined and with posterior acoustic shadowing. They are T1 hypointense, T2 bright and with postcontrast wall enhancement. Corpus luteal cysts and hemorrhagic cysts may have walls thicker than 3 mm. The presence of blood products may result in the T1 hyperintense appearance of hemorrhagic cysts. 
Parovarian cysts are developmental remnants of the mesonephric ducts. The features of parovarian cysts are similar to follicular cysts, except that they do not regress on US follow-up. On MRI, the ovary can be identified separate from the lesion.
Normal and Abnormal PET-CT Findings in the Female Pelvis
The applications of 2-[fluorine 18] fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) imaging in the management of gynecological malignancy are manifold. PET, when concurrently performed and fused with CT images (PET/CT), helps in the detection of lymph node spread of cervical cancer, to assess tumor volume and to determine local control after radiotherapy.  The utility of PET in the detection of malignancy stems from the ability to differentiate tissues with increased metabolism, such as cancer cells. Several physiologic processes with increased metabolism show abnormally high PET activity leading to misdiagnoses. Both the normal endometrium and the ovary show varying uptake depending upon the menstrual phase. Therefore, for routine clinical interpretation of PET/CT images, one must know the appearance of normal physiologic uptake in the endometrium and ovary.
In a premenopausal woman with normal menstrual cycle and no gynecological malignancy, physiological endometrial uptake has two peaks. One peak is at mid-cycle  and the other on the first three days of the menstrual flow. ,, Standardized uptake values [SUV] of 5 ± 3.2 during menses and 3.7 ± 0.9 in ovulatory phase are normal.  The endometrial uptake appears like an inverted triangle on axial images and like a curvilinear or ellipsoid over the urinary bladder in sagittal images.  Neither hormonal contraceptives nor intrauterine contraceptive devices increase the endometrial uptake significantly.  In patients with menstrual irregularities, oligomenorrhea has been shown to have high SUV similar to those seen during the normal ovulatory phase endometrium, and amenorrhea has been shown to have values similar to postmenopausal endometrium. FDG uptake should not be seen in the endometrium of postmenopausal women. The SUVs in postmenopausal women taking HRT was not seen to be higher in a study by Lerman et al.
In premenopausal women, physiological ovarian uptake of FDG PET is seen in the late follicular, ovulatory and early luteal phase of the menstrual cycle.  Most commonly increased FDG uptake is seen during the early luteal phase [Figure 5]. In women with a known malignancy, FDG accumulations in corpus luteal cysts have been misinterpreted as metastasis to iliac lymph nodes. ,, Physiological ovarian uptake is often unilateral and appears round to oval with an SUV greater than 3. Lerman et al, found that an SUV of 7.9 separated benign from malignant ovarian uptake; however, the sensitivity for the detection of malignancy is only 57%. Disappearance on imaging performed soon after the subsequent menstrual cycle most reliably confirms the physiologic nature of the cyst. In order to avoid the confusion arising from functional ovarian uptake, PET/CT scans in premenopausal women should be scheduled in the first week after menses. Any FDG accumulation in the ovaries in a postmenopausal woman should be considered suspicious for malignancy.
Heterogeneous and moderately intense FDG uptake has been seen in uterine fibroids. ,,,,,, The cause of this increased uptake may be related to the presence of receptors for certain growth factors and to the high endometrial and cervical tissue glycogen in myomatous uteri. , No correlation was seen between the uptake in the fibroid and the menstrual phase.  Kitajima et al, recently showed that the size of the fibroid, and presence of degeneration did not significantly correlate with SUV. However, a negative correlation was seen with age.
The utility of PET/CT in cervical cancers is well studied. Although MRI is more sensitive in assessing local spread of cervical cancers, PET/CT has a high sensitivity in detecting nodal metastases. The SUV max of the primary tumor can predict the presence of lymph node involvement, tumor persistence following treatment and pelvic recurrence. A higher SUV max also indicates a more aggressive tumor, and hence, the need for more aggressive treatment. , In ovarian cancer patients, PET/CT is useful to detect macroscopic recurrence of ovarian cancer  and has been shown to be more accurate than CT alone.  In advanced disease, it can be used to predict response of to neoadjuvant therapy and survival.  PET/CT has been shown to modify treatment in post-therapy surveillance of endometrial cancer in 33-73% patients in various studies. ,, Preliminary studies investigating the utility of PET/CT in uterine sarcoma,  vulvar  and vaginal cancer  and gestational trophoblastic disease , have shown promising results. The role of PET/CT in gynecological malignancy is evolving from a diagnostic tool into one that predicts survival and modifies treatment.
In postmenopausal women with AUB, endometrial thickness >5 mm on TVUS warrants further investigation.
In pre- and postmenopausal women with AUB, sonohysterography is useful in detecting endometrial polyps and submucosal fibroids.
For adnexal masses indeterminate on US, MRI has been shown to be the next best test for definitive characterization, especially if the lesion is thought to be benign.
In premenopausal women imaged with PET/CT hypermetabolic tracer uptake is seen in the normal endometrium and ovary during certain phases of the menstrual cycle.
In postmenopausal women imaged with PET/CT, hypermetabolic tracer uptake in the endometrium or the ovary should be considered suspicious for underlying pathology.
|1||Bayer SR, DeCherney AH. Clinical manifestations and treatment of dysfunctional uterine bleeding. JAMA 1993;269:1823-8.|
|2||Silverstone AC. Cancers of the endometrium and fallopian tube. In: Souhami RL, Tannock I, Hohenberger P, Horiot JC, editors. Oxford Textbook of Oncology. 2nd ed. London: Oxford University Press; 2001.|
|3||Duffield SE, Picker RH. Ultrasonic evaluation of the uterus in the normal menstrual cycle. Med Ultrasound 1981;5:70-4.|
|4||Fleischer AC. Transvaginal sonography of endometrial disorders: An overview. Radiographics 1998;18:923-30.|
|5||Lyons EA, Gratton D, Harrington C. Transvaginal sonography of normal pelvic anatomy. Radiol Clin North Am 1992;30:663-72.|
|6||Fleischer AC, Gordon AN, Entman SS, Kepple DM. Transvaginal sonography (TVS) of the endometrium: Current and potential clinical applications. Crit Rev Diagn Imaging 1990;30:85-110.|
|7||Smith P, Bakos O, Heimer G, Ulmsten U. Transvaginal ultrasound for identifying endometrial abnormality. Acta Obstet Gynecol Scand 1991;70:591-4.|
|8||Nalaboff KM, Pellerito JS, Ben-Levi E. Imaging the endometrium: Disease and normal variants. Radiographics 2001;21:1409-24.|
|9||Smith-Bindman R, Kerlikowske K, Feldstein VA, Subak L, Scheidler J, Segal M, et al. Endovaginal ultrasound to exclude endometrial cancer and other endometrial abnormalities. JAMA 1998;280:1510-7.|
|10||Critchley HO, Warner P, Lee AJ, Brechin S, Guise J, Graham B. Evaluation of abnormal uterine bleeding: Comparison of three outpatient procedures within cohorts defined by age and menopausal status. Health Technol Assess 2004;8:1-139.|
|11||Clark TJ, Voit D, Gupta JK, Hyde C, Song F, Khan KS. Accuracy of hysteroscopy in the diagnosis of endometrial cancer and hyperplasia: A systematic quantitative review. JAMA 2002;288:1610-21.|
|12||de Kroon CD, de Bock GH, Dieben SW, Jansen FW. Saline contrast hysterosonography in abnormal uterine bleeding: A systematic review and meta-analysis. BJOG 2003;110:938-47.|
|13||van Dongen H, de Kroon CD, Jacobi CE, Trimbos JB, Jansen FW. Diagnostic hysteroscopy in abnormal uterine bleeding: A systematic review and meta-analysis. BJOG 2007;114:664-75.|
|14||Weigel M, Friese K, Strittmatter HJ, Melchert F. Measuring the thickness: Is that all we have to do for sonographic assessment of endometrium in postmenopausal women? Ultrasound Obstet Gynecol 1995;6:97-102. |
|15||Mossa B, Imperato F, Marziani R, Perniola F, Melluso J, Perniola G, et al. Hormonal replacement therapy and evaluation of intrauterine pathology in postmenopausal women: A ten-year study. Eur J Gynaecol Oncol 2003;24:507-12.|
|16||Fong K, Kung R, Lytwyn A, Trudeau M, Chapman W, Nugent P, et al. Endometrial evaluation with transvaginal US and hysterosonography in asymptomatic postmenopausal women with breast cancer receiving tamoxifen. Radiology 2001;220:765-73.|
|17||Hann LE, Giess CS, Bach AM, Tao Y, Baum HJ, Barakat RR. Endometrial thickness in tamoxifen-treated patients: Correlation with clinical and pathologic findings. AJR Am J Roentgenol 1997;168:657-61.|
|18||Davis PC, O'Neill MJ, Yoder IC, Lee SI, Mueller PR. Sonohysterographic findings of endometrial and subendometrial conditions. Radiographics 2002;22:803-16.|
|19||Dubinsky TJ, Parvey HR, Gormaz G, Makland N. Transvaginal hysterosonography in the evaluation of small endoluminal masses. J Ultrasound Med 1995;14:1-6.|
|20||Bradley LD, Falcone T, Magen AB. Radiographic imaging techniques for the diagnosis of abnormal uterine bleeding. Obstet Gynecol Clin North Am 2000;27:245-76.|
|21||Goldstein SR, Zeltser I, Horan CK, Snyder JR, Schwartz LB. Ultrasonography-based triage for perimenopausal patients with abnormal uterine bleeding. Am J Obstet Gynecol 1997;177:102-8.|
|22||Fong K, Causer P, Atri M, Lytwyn A, Kung R. Transvaginal US and hysterosonography in postmenopausal women with breast cancer receiving tamoxifen: Correlation with hysteroscopy and pathologic study. Radiographics 2003;23:137-50|
|23||Leibman AJ, Kruse B, McSweeney MB. Transvaginal sonography: Comparison with transabdominal sonography in the diagnosis of pelvic masses. AJR Am J Roentgenol 1988;151:89-92.|
|24||Reles A, Wein U, Lichtenegger W. Transvaginal color Doppler sonography and conventional sonography in the preoperative assessment of adnexal masses. J Clin Ultrasound 1997;25:217-25.|
|25||Ferrazzi E, Zanetta G, Dordoni D, Berlanda N, Mezzopane R, Lissoni AA. Transvaginal ultrasonographic characterization of ovarian masses: Comparison of five scoring systems in a multicenter study. Ultrasound Obstet Gynecol 1997;10:192-7.|
|26||Kurjak A, Predanic M. New scoring system for prediction of ovarian malignancy based on transvaginal color Doppler sonography. J Ultrasound Med 1992;11:631-8.|
|27||Franchi M, Beretta P, Ghezzi F, Zanaboni F, Goddi A, Salvatore S. Diagnosis of pelvic masses with transabdominalcolor Doppler, CA 125 and ultrasonography. Acta Obstet Gynecol Scand 1995;74:734-9.|
|28||Hata K, Hata T, Manabe A, Sugimura K, Kitao M. A critical evaluation of transvaginal Doppler studies, transvaginal sonography, magnetic resonance imaging, and CA 125 in detecting ovarian cancer. Obstet Gynecol 1992;80:922-6.|
|29||Kinkel K, Lu Y, Mehdizade A, Pelte MF, Hricak H. Indeterminate ovarian mass at US: incremental value of second imaging test for characterization-meta-analysis and Bayesian analysis. Radiology 2005;236:85-94.|
|30||Jeong YY, Outwater EK, Kang HK. Imaging evaluation of ovarian masses. Radiographics 2000;20:1445-70.|
|31||Riccio TJ, Adams HG, Munzing DE, Mattrey RF. Magnetic resonance imaging as an adjunct to sonography in the evaluation of the female pelvis. Magn Reson Imaging 1990;8:699-704. |
|32||Scoutt LM, McCarthy SM, Lange R, Bourque A, Schwartz PE. MR evaluation of clinically suspected adnexal masses. J Comput Assist Tomogr 1994;18:609-18.|
|33||Weinreb JC, Barkoff ND, Megibow A, Demopoulos R. The value of MR imaging in distinguishing leiomyomas from other solid pelvic masses when sonography is indeterminate. AJR Am J Roentgenol 1990;154:295-9.|
|34||Young RH, Scully RE. Sex-cord stromal, steroid cell and other ovarian tumors with endocrine, paraendocrine and paraneoplastic manifestations. In: Kurman RJ editor. Blaustein's Pathology of the Female Genital Tract. 4th ed. New York: Springer Verlag; 1994. p. 783-847. |
|35||Sala EJ, Atri M. Magnetic resonance imaging of benign adnexal disease. Top Magn Reson Imaging 2003;14:305-27.|
|36||Patel MD. Feldstein VA, Chen DC, Lipson SD, Filly RA. Endometriomas: Diagnostic performance of US. Radiology 1999;210:739-45.|
|37||Pascual MA, Tresserra F, Lopez-Marin L, Ubeda A, Grases PJ, Dexeus S. Role of color Doppler ultrasonography in the diagnosis of endometriotic cyst. J Ultrasound Med 2000;19:695-9.|
|38||Takeuchi M, Matsuzaki K, Uehara H, Nishitani H. Malignant transformation of pelvic endometriosis: MR imaging findings and pathologic correlation. Radiographics 2006;26:407-17.|
|39||Outwater EK, Siegelman ES, Hunt JL. Ovarian teratomas: Tumor types and imaging characteristics. Radiographics 2001;21:475-90.|
|40||Stevens SK, Hricak H. Campos Z. Teratoma versus cystic hemorrhagic adnexal lesions: Differentiation with proton-selective fat-saturation. MR imaging. Radiology 1993;186:481-8.|
|41||Nakayama T, Yoshimitsu K, Irie H, Aibe H, Tajima T, Nishie A, et al. Diffusion-weighted echo-planar MR imaging and ADC mapping in the differential diagnosis of ovarian cystic masses: Usefulness of detecting keratinoid substances in mature cystic teratomas. J Magn Reson Imaging 2005;22:271-8.|
|42||Timor-Tritsch IE, Lerner JP, Monteagudo A, Murphy KE, Heller DS. Transvaginal sonographic markers of tubal inflammatory disease. Ultrasound Obstet Gynecol 1998;12:56-66.|
|43||Kim SH, Kim SH, Yang DM, Kim KA. Unusual causes of tubo-ovarian abscess: CT and MR imaging findings. Radiographics 2004;24:1575-89.|
|44||Ha HK, Lim GY, Cha ES, Lee HG, Ro HJ, Kim HS, et al. MR imaging of tubo-ovarian abscess. Acta Radiol 1995;36:510-4.|
|45||Guerriero S, Ajossa S, Mais V, Angiolucci M, Paoletti AM, Melis GB. Role of transvaginal sonography in the diagnosis of peritoneal inclusion cysts. J Ultrasound Med 2004;23:1193-200.|
|46||Jain KA. Imaging of peritoneal inclusion cysts. AJR Am J Roentgenol 2000;174:1559-63. |
|47||Nakamoto Y, Eisbruch A, Achtyes ED, Sugawara Y, Reynolds KR, Johnston CM, et al. Prognostic value of positron emission tomography using F-18-fluorodeoxyglucose in patients with cervical cancer undergoing radiotherapy. Gynecol Oncol 2002;84:289-95.|
|48||Lerman H, Metser U, Grisaru D, Fishman A, Lievshitz G, Even-Sapir E. Normal and abnormal 18F-FDG endometrial and ovarian uptake in pre- and postmenopausal patients: assessment by PET/CT. J Nucl Med 2004;45:266-71.|
|49||Nishizawa S, Inubushi M, Okada H. Physiological 18F-FDG uptake in the ovaries and uterus of healthy female volunteers. Eur J Nucl Med Mol Imaging 2005;32:549-56.|
|50||Chander S, Meltzer CC, McCook BM. Physiologic uterine uptake of FDG during menstruation demonstrated with serial combined positron emission tomography and computed tomography. Clin Nucl Med 2002;27:22-4.|
|51||Ames J, Blodgett T, Meltzer C. 18F-FDG uptake in an ovary containing a hemorrhagic corpus luteal cyst: False-positive PET/CT in a patient with cervical carcinoma. AJR Am J Roentgenol 2005;185:1057-9.|
|52||Bagga S. A corpus luteal cyst masquerading as a lymph node mass on PET/CT scan in a pregnant woman with an anterior mediastinal lymphomatous mass. Clin Nucl Med 2007;32:649-51.|
|53||Ho KC, Ng KK, Yen TC, Chou HH. An ovary in luteal phase mimicking common iliac lymph node metastasis from a primary cutaneous peripheral primitive neuroectodermal tumor as revealed by 18-fluoro-2-deoxyglucose positron emission tomography. Br J Radiol 2005;78:343-5.|
|54||Lee WL, Liu RS, Yuan CC, Chao HT, Wang PH. Relationship between gonadotropin-releasing hormone agonist and myoma cellular activity: Preliminary findings on positron emission tomography. Fertil Steril 2001;75:638-9.|
|55||Ak I, Ozalp S, Yalηin OT, Zor E, Vardareli E. Uptake of 2-[18F]fluoro-2-deoxy-D-glucose in uterine leiomyoma: Imaging of four patients by coincidence positron emission tomography. Nucl Med Commun 2004;25:941-5.|
|56||Shida M, Murakami M, Tsukada H, Ishiguro Y, Kikuchi K, Yamashita E, et al. F-18 fluorodeoxyglucose uptake in leiomyomatous uterus. Int J Gynecol Cancer 2007;17:285-90.|
|57||Lin CY, Ding HJ, Chen YK, Liu CS, Lin CC, Kao CH. F-18 FDG PET in detecting uterine leiomyoma. Clin Imaging 2008;32:38-41.|
|58||Kitajima K, Murakami K, Yamasaki E, Kaji Y, Sugimura K. Standardized uptake values of uterine leiomyoma with 18F-FDG PET/CT: Variation with age, size, degeneration, and contrast enhancement on MRI. Ann Nucl Med 2008;22:505-12.|
|59||Chura JC, Truskinovsky AM, Judson PL, Johnson L, Geller MA, Downs LS Jr. Positron emission tomography and leiomyomas: Clinicopathologic analysis of 3 cases of PET scan-positive leiomyomas and literature review. Gynecol Oncol 2007;104:247-52.|
|60||Kao CH. FDG uptake in a huge uterine myoma. Clin Nucl Med 2003;28:249.|
|61||Jover R, Lourido D, Gonzalez C, Rojo A, Gorospe L, Alfonso JM. Role of PET/CT in the evaluation of cervical cancer. Gynecol Oncol 2008;110:S55-9.|
|62||Kidd EA, Siegel BA, Dehdashti F, Grigsby PW. The standardized uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival. Cancer 2007;110:1738-44.|
|63||Bristow RE, del Carmen MG, Pannu KH Cohade C, Zahurak ML, Fishman EK, et al. Clinically occult ovarian cancer: Patient selection for secondary cytoreductive surgery using combined PET/CT. Gynecol Oncol 2003;90:519-28.|
|64||Sebastian S, Lee SI, Horowitz NS, Scott JA, Simeone JF, Fischman AJ, et al. Comparison of hybrid PET-CT and sixteen-slice multidetector CT in detecting ovarian cancer recurrence. Abdom Imaging 2008;33:112-8.|
|65||Avril N, Sassen S, Schmalfeldt B, Naehrig J, Rutke S, Weber WA, et al. Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced stage ovarian cancer. J Clin Oncol 2005;23:7445- 53.|
|66||Belhocine T, de Barsy C, Hustinx R, Willerns-Foidart J. Usefulness of (18)F-FDG PET in the posttherapy surveillance of endometrial carcinoma. Eur J Nucl Med Mol Imaging 2002;29:1132-9.|
|67||Saga T, Higashi T, Ishimori T, Mamede M, Nakamoto Y, Mukai T, et al. Clinical value of FDG-PET in the follow up of postoperative patients with endometrial cancer. Ann Nucl Med 2003;17:197-203.|
|68||Chao A, Chang YC, Ng KK, Hsueh S, Huang HJ, Chou HH, et al. 18F-FDG PET in the management of endometrial cancer. Eur J Nucl Med 2006;33:36-44.|
|69||Umesaki N, Tanaka T, Miyama M, Kawamura N, Ogita S, Kawabe J, et al. Positron emission tomography with (18)F-fluorodeoxyglucose of uterine sarcoma: A comparison with magnetic resonance imaging and power Doppler imaging. Gynecol Oncol 2001;80:372-7.|
|70||Cohn DE, Dehdashti F, Gibb RK, Mutch DG, Rader JS, Siegel BA, et al. Prospective evaluation of positron emission tomography for the detection of groin node metastases from vulvar cancer. Gynecol Oncol 2002;85:179-84.|
|71||Lamoreaux WT, Grigsby PW, Dehdashti F, Zoberi I, Powell MA, Gibb RK, et al. FDG-PET evaluation of vaginal cancer. Int J Radiat Oncol Biol Phys 2005;62:733-7.|
|72||Chang TC, Yen TC, Li YT, Wu YC, Chang YC, Ng KK, et al. 18F-fluoro-D-deoxyglucose positron emission tomography of trophoblastic tumor: A pilot study. Eur J Nucl Med Mol Imaging 2006;33:156-63.|
|73||Sironi S, Picchio M, Mangili G, Garavaglia E, Zangheri B, Messa C, et al. [18F]fluorodeoxyglucose positron emission tomography as a useful indicator of metastatic gestational trophoblastic tumor: preliminary results in three patients. Gynecol Oncol 2003;91:226-30.|